The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW

BACKGROUND: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in patients with axial spondyloarthritis (axSpA). C-VIEW investigates the impact of the Fc-free TNF inhibitor certolizumab pegol (CZP) on AAU flares in patients with active axSpA at high risk of recurrent AAU....

Descripción completa

Detalles Bibliográficos
Autores principales: van der Horst-Bruinsma, Irene, van Bentum, Rianne, Verbraak, Frank D, Rath, Thomas, Rosenbaum, James T, Misterska-Skora, Maria, Hoepken, Bengt, Irvin-Sellers, Oscar, VanLunen, Brenda, Bauer, Lars, Rudwaleit, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299504/
https://www.ncbi.nlm.nih.gov/pubmed/32371433
http://dx.doi.org/10.1136/rmdopen-2019-001161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299504/
https://www.ncbi.nlm.nih.gov/pubmed/32371433
http://dx.doi.org/10.1136/rmdopen-2019-001161

Ejemplares similares